{
    "clinical_study": {
        "@rank": "78878", 
        "brief_summary": {
            "textblock": "Roxithromycin is effective in the treatment of intracellular organisms, including chlamydia\n      and mycoplasma, and exhibits anti-inflammatory and immunomodulatory effects on respiratory\n      diseases. To explore the potential therapeutic benefit of roxithromycin in chronic\n      prostatitis/chronic pelvic pain syndrome (CP/CPPS), this study compared the effect of\n      roxithromycin with ciprofloxacin and aceclofenac."
        }, 
        "brief_title": "Clinical Efficacy of Roxithromycin in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome", 
        "completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Chronic Prostatitis", 
            "Chronic Pelvic Pain Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Pelvic Pain", 
                "Prostatitis", 
                "Chronic Disease", 
                "Somatoform Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "A total of 75 patients with CP/CPPS were randomized to three groups in open-label: group 1,\n      ciprofloxacin; group 2, aceclofenac; and group 3, roxithromycin. The patients were treated\n      for 4 weeks and were subsequently followed for 12 weeks. Changes from baseline in the total\n      and domain scores of the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) were evaluated."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of category IIIa of IIIb chronic prostatitis\n\n          -  NIH-CPSI (National Institute of Health Chronic Prostatitis Symptom Index) score \u2265 15\n\n        Exclusion Criteria:\n\n          -  Urinary tract infection or uropathogen within the past 12 months\n\n          -  Serious medical problems\n\n          -  NIH consensus exclusion criteria13 (presence of active urethritis, urogenital cancer,\n             urinary tract disease, functionally significant urethral stricture, neurological\n             disease affecting the bladder, etc.)\n\n          -  Drug therapy that might affect lower urinary tract functions within the past 3 months"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "75"
            }
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01843946", 
            "org_study_id": "Rulid-2011"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 30, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Suwon", 
                    "country": "Korea, Republic of", 
                    "zip": "442-723"
                }, 
                "name": "The Catholic University of Korea, St. Vincent's Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "overall_official": {
            "affiliation": "The Catholic University of Korea ST.Vincent's hospital", 
            "last_name": "Hyun-Sop Choe, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Changes from baseline in the total and domain scores of the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) were evaluated.", 
            "measure": "NIH-CPSI score", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01843946"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The Catholic University of Korea", 
            "investigator_full_name": "Hyun-Sop Choe", 
            "investigator_title": "Doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "The Catholic University of Korea", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Catholic University of Korea", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2011", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2013"
    }
}